Lilly Teams Up With Boehringer Ingelheim To Boost Abemaciclib
Executive Summary
The two big pharmas are working together in oncology in an effort to advance combination therapies in both their growing, but young oncology pipelines.
You may also be interested in...
Boehringer Increasingly Looking Outside For Oncology Growth
The private company has stressed home-grown candidates, but it's making more external plays as it builds oncology as one of the pillars of the business.
Lilly's Abemaciclib Hit Leaves It Down But Not Out
Continuation of Phase III MONARCH 2 study, with no early termination for efficacy, may mean a delay in filing and a tougher competitive outlook against Pfizer's Ibrance and Novartis' ribociclib.
Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance
Although Jardiance is supported by outcomes data, it has not yet been incorporated into labeling, nor has it translated into greater sales.